Literature DB >> 17629022

Radiofrequency ablation versus percutaneous microwave coagulation therapy for small hepatocellular carcinomas: a retrospective comparative study.

Kerji Ohmoto1, Naoko Yoshioka, Yasuyuki Tomiyama, Norikuni Shibata, Tomoya Kawase, Koji Yoshida, Makoto Kuboki, Shinichiro Yamamoto.   

Abstract

BACKGROUND/AIMS: Although local ablation procedures are useful in eradication treatment for small hepatocellular carcinoma (HCC), there have only been a few clinical studies comparing the response to radiofrequency ablation (RFA) and percutaneous microwave coagulation therapy (PMCT). We evaluated the clinical effect and safety of these two procedures for the treatment of small HCCs measuring 2cm or less in diameter.
METHODOLOGY: Twenty-four patients with HCC who were treated by RFA and were compared with 39 patients with HCC who underwent PMCT. These procedures were repeated until complete tumor necrosis was achieved. The therapeutic and adverse effects were retrospectively compared between the two procedures.
RESULTS: (1) There were significantly fewer treatment sessions (P < 0.001) in the RFA group than the PMCT group, and the necrotic area was significantly larger (P < 0.001) in the former group. (2) The local recurrence rate was significantly lower (P = 0.012) after RFA than after PMCT, even though the ectopic recurrence rate showed no significant difference. 3) The cumulative survival rate was significantly higher (P = 0.028) in the RFA group. (4) The incidence of pain and fever after treatment was significantly higher after PMCT than after RFA. Bile duct injury and pleural effusion were also more frequent in the PMCT group.
CONCLUSIONS: RFA is more useful than PMCT in the treatment of small HCCs because it is minimally invasive and achieves a low local recurrence rate, high survival rate, and extensive necrosis after only a few treatment sessions.

Entities:  

Mesh:

Year:  2007        PMID: 17629022

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  7 in total

1.  Thermal ablation for unresectable liver tumours, time to move forward?

Authors:  Gianpiero Gravante
Journal:  World J Gastrointest Surg       Date:  2010-01-27

Review 2.  Evolution of surgical microwave ablation for the treatment of colorectal cancer liver metastasis: review of the literature and a single centre experience.

Authors:  Stefan Stättner; Florian Primavesi; Vincent S Yip; Robert P Jones; Dietmar Öfner; Hassan Z Malik; Stephen W Fenwick; Graeme J Poston
Journal:  Surg Today       Date:  2014-03-16       Impact factor: 2.549

3.  Percutaneous radiofrequency versus microwave ablation for management of hepatocellular carcinoma: a randomized controlled trial.

Authors:  Ahmed Kamal; Amr Aly Abd Elmoety; Yousri Abdel Meguid Rostom; Mohamed Said Shater; Sameh Aldesoky Lashen
Journal:  J Gastrointest Oncol       Date:  2019-06

4.  Radiofrequency ablation combined with transarterial chemoembolization versus hepatectomy for patients with hepatocellular carcinoma within Milan criteria: a retrospective case-control study.

Authors:  A K Bholee; K Peng; Z Zhou; J Chen; L Xu; Y Zhang; M Chen
Journal:  Clin Transl Oncol       Date:  2017-01-09       Impact factor: 3.405

5.  Recent advances in radiofrequency ablation for the management of hepatocellular carcinoma.

Authors:  Takashi Himoto; Kazutaka Kurokohchi; Seishiro Watanabe; Tsutomu Masaki
Journal:  Hepat Mon       Date:  2012-10-10       Impact factor: 0.660

6.  The effect of lipiodol deposition in HCC after TACE on the necrosis range of PMCT.

Authors:  HongLiang Sun; JiaYan Ni; XiongYing Jiang; Dong Chen; YaoTing Chen; LinFeng Xu
Journal:  Onco Targets Ther       Date:  2017-08-01       Impact factor: 4.147

7.  Minimally invasive image-guided therapy for inoperable hepatocellular carcinoma: What is the evidence today?

Authors:  Beatrijs A Seinstra; Otto M van Delden; Karel J van Erpecum; Richard van Hillegersberg; Willem P Th M Mali; Maurice A A J van den Bosch
Journal:  Insights Imaging       Date:  2010-06-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.